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Abstract
The classic model of tumor suppression implies that malignant transformation requires full 'two-
hit' inactivation of a tumor suppressor gene. However, more recent work in mice has led to the 
proposal of a "continuum" model that involves more fluid concepts such as gene dosage-sensitivity 
and tissue specificity. Mutations in the tumor suppressor gene VHL are associated with a complex 
spectrum of conditions. Homozygotes or compound heterozygotes for the R200W germline 
mutation in VHL have Chuvash polycythemia, whereas heterozygous carriers are free of disease. 
Individuals with classic, heterozygous VHL mutations have von Hippel-Lindau disease and are at 
high risk of multiple tumors (e.g. CNS hemangioblastomas, pheochromocytoma, renal cell 
carcinoma). We report here an atypical family bearing two VHL gene mutations in cis (R200W 
and R161Q), together with phenotypic analysis, structural modeling, functional and transcriptomic 
studies of these mutants in comparison to classical mutants involved in the different VHL 
phenotypes. We demonstrate that the complex pattern of disease manifestations observed in VHL 
syndrome is perfectly correlated with a gradient of pVHL dysfunction in hypoxia signaling 
pathways. Thus, by studying naturally occurring familial mutations, our work validates in humans 
the "continuum" model of tumor suppression.
Introduction
Over the past 30 years, the genetics of inherited cancer syndromes associated with germline 
mutations in tumor suppressor genes (TSG) have been dominated by Knudson’s “two-hit” 
model. This model proposed that inherited cancers associated with TSG occur after its total 
loss of function, in both alleles. The first genetic event is inherited and, in a second step, the 
loss of the wild type allele is acquired and induces further steps of oncogenesis, with 
somatic events and emergence of cancer. Berger, Knudson and Pandolfi recently proposed a 
new « continuum » model that accounts for subtle dosage effects of tumour suppressors (1). 
This model introduces concepts such as gene dosage-sensitivity, specific phenotype of 
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heterozygote cells (haplo-insufficiency) and tissue specificity. Some mice models (mutated 
for Pten or p53) illustrate this model, however, the notion that even partial inactivation of 
tumor suppressors can critically contribute to tumorigenesis in humans has gained only 
limited acceptance in the scientific community. One puzzling case of inherited cancer 
syndrome is the von Hippel-Lindau (VHL) disease associated with VHL mutations. VHL is 
a TSG, and heterozygous inherited mutations are associated with multiple phenotypes. 
Depending on the mutation, patients are predisposed to multiple tumors, including renal 
cancers (that have lost the wild type allele), and/or pheochromocytomas (that do not always 
lose the second allele), and in cases with particular mutations, patients are free of cancer. 
This wide range of patient phenotypes seemed a good example to test the hypothesis of a 
continuum model in humans.
The von Hippel-Lindau gene (VHL) is involved in many functions, the most studied being 
the regulation of the cellular oxygen-sensing pathway. The main actor of this pathway is the 
heterodimeric transcription factor HIF (Hypoxia Inducible Factor). Under normal oxygen 
tension, the alpha subunits of HIF (HIF-1α, 2 α and 3α) are hydroxylated by the 
dioxygenases PHD (PHD1, 2 and 3). The hydroxylated HIF-α are then targeted by the VHL 
protein (pVHL), (the substrate recognition subunit of an E3 ubiquitin ligase complex) that 
promotes HIF-α for proteasomal degradation (2, 3). In contrast, in hypoxia, the HIF-α 
subunit is stabilized and binds to the HIF-β subunit to form an active transcription factor that 
regulates expression of hundreds of genes implicated notably in angiogenesis, 
erythropoiesis, cell-survival and tumor progression.
More than 160 distinct germline mutations in the VHL gene have been identified and are 
associated with distinct phenotypes (Supplementary Fig. S1). Heterozygous mutations 
predispose to VHL disease, the leading cause of hereditary kidney cancer. Patients with 
VHL disease are at high risk of developing clear cell renal cell carcinomas (ccRCC), central 
nervous system (CNS) and retinal hemangioblastomas, pheochromocytomas, 
paragangliomas, cysts and neuroendocrine tumors of the pancreas, and tumours of the 
endolymphatic sac. Studies of genotype-phenotype correlations originally established two 
types of phenotypes based on the risk of developing pheochromocytomas (4, 5): VHL 
Type-1 (low risk) and VHL Type-2 (high risk). Type-2 disease is subdivided into three 
categories corresponding to a low (2A) or high risk (2B) of developing ccRCC, or to a risk 
of pheochromocytomas and paragangliomas only (2C). VHL Type-2 disease is associated 
with VHL missense mutations that lead to severe (Types-2A and 2B) or weaker (Type-2C) 
alterations in pVHL function (6, 7). In contrast, VHL Type-1 disease is associated with 
mutations that strongly impair the structure of pVHL or result in the complete absence of the 
protein (truncated proteins or total gene deletion). The analysis of cases with gene deletions 
demonstrated that VHL-loss alone is sufficient to predispose to ccRCC development, and 
that the loss of a larger region (encompassing the HSPCC300 gene) would have a protective 
role (8).
Whereas germline mutations in the VHL gene commonly predispose patients to the 
development of multiple tumors, a third category of phenotype has been described in 
Russian patients from the Chuvash region. These patients are homozygotes for the VHL-
R200W mutation (considered less severe than classic VHL mutants (9, 10)), and present 
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with a congenital erythrocytosis (excess of red cell production) named Chuvash 
polycythemia. Survival in the Chuvash patients was found to be reduced compared to control 
groups due to higher rates of arterial and venous thromboses, and to haemorrhagic events 
(11). This specific VHL-R200W mutation has also been identified in combination with other 
VHL mutations (compound heterozygosity) (Supplementary Table S1) and, since then, other 
missenses VHL mutations have been described (always different from the VHL mutation 
involved in severe von Hippel-Lindau disease) (Table S2) (12). It is known that the HIF 
signaling is involved in Chuvash polycythemia (9, 10, 13, 14) but the exact mechanisms that 
may explain the heterogeneity of the clinical phenotype (differences in serum EPO level and 
propensity to develop thrombosis and pulmonary arterial hypertension (PAH)) is still 
unexplained (15, 16). However, a characteristic of these patients is the total absence of tumor 
development (11, 15, 16). Noteworthily, the R200W mutation is always transmitted 
(excepted in one case) (17) within a 340-kilobases haplotype inherited 14,000 to 62,000 
years ago from a single founder event (18). The absence of tumor development in patients 
carrying the R200W mutation raised the possibility of the presence of a protective element 
within this core haplotype (11).
Heterozygous carriers for VHL-R200W either have no symptoms or rarely develop 
erythrocytosis, but they do not develop tumors, except for two cases of isolated CNS 
hemangioblastoma and, intriguingly, one family with apparently typical VHL disease, 
suggesting an additional level of complexity to genotype-phenotype correlations (19, 20). 
Since it was first reported, this family has puzzled the medical and scientific VHL 
community (see references in Supplementary Table S1). In order to better understand the 
absence of tumors in the heterozygous carriers of the VHL-R200W mutation and to 
determine the cause of cancer development in this family (loss of a protective event or 
presence an additional event), we have carried out an in-depth study of family members and 
compared our findings to what is observed with classic VHL mutations.
Material and Methods
Patients
Through the French-speaking clinical VHL network and after agreement from the local 
Ethics Committee was obtained, our laboratory retraced this family (V1000 (19), 1000F 
(20)). We collected blood samples from all family members for genetic analysis and 
erythropoietin quantification. All participants had signed an informed consent form.
Sequencing
Genomic DNA was extracted from peripheral blood and purified on a spin column (Qiagen). 
Screening for the VHL mutations (three coding exons and exon-intron junctions) and the 
eight Single Nucleotide Polymorphisms (SNP) described in Liu et al., 2004 (18) was 
performed by direct capillary Sanger sequencing method described in Supplementary Data.
Molecular dynamics (MD) simulations
The starting models of pVHL were constructed from the crystal structure solved by Min and 
co-workers (2002) (PDB ID code 1lm8)(21). Mutant models were generated from the wild-
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type model by in silico substitutions of the arginine (R) in positions 161 and 200, with a 
glutamine (Q) and a tryptophan (W) respectively. All the details are given in Supplementary 
Data.
In vitro analysis of HIF-1α/pVHL binding
The HA-tagged pVHL protein was synthesized in vitro and incubated with a hydroxylated-
biotinylated peptide corresponding to the HIF-1α oxygen dependant domain. HA-
pVHL/HIF complexes were immunoprecipitated with streptavidin beads and analyzed by 
Nu-Page migration (Invitrogen). The hydroxylated peptides bound to HA-pVHL were 
revealed by immunoblotting using an HA specific antibody (Santa Cruz Biotechnology). 
Details are described in Supplementary Data.
VHL mutants construction
To avoid cell death during reintroduction of VHL in the VHL-defective 786.O cell line (22), 
we used an tetracycline (or doxycycline) inducible system to study the VHL mutants. The 
ViraPower T-REX Lentiviral Expression System (Invitrogen) was used to construct 
inducible lenti-vectors encoding non-tagged VHL. The vectors were stably transfected into 
786.O cells that overexpresses HIF-2α. The 786.O cells are a gift from the laboratory of Pr 
Kaelin (Boston). They have been genotyped by direct sequencing for the VHL gene after 
reception in our laboratory. Clones with equivalent VHL mRNA expression were selected 
for micro-array study. All the details are indicated in Supplementary Data.
Transcriptomic study
RNA was extracted using Trizol reagent (Sigma) and purified on Qiagen columns. 500 ng of 
total RNA from each RNA sample was amplified and labelled with two fluorescent dyes 
(Cy5 and Cy3). Labelled cRNA were hybridized to the Agilent Human Whole Genome 
Oligo Microarray format 4x44K (Agilent Technologies), prior to washing and scanning. All 
hybridizations were performed in duplicate with dye swap to eliminate possible dye bias. 
Data were extracted from scanned images using Feature Extraction software (Agilent) with 
default settings. Data from all hybridizations were analysed with Rosetta Resolver software. 
The microarray data related to this paper have been submitted to the Array Express data 
repository at the European Bioinformatics Institute (http://www.ebi.ac.uk/arrayexpress/) 
under the accession number E-MTAB-1269. Details are described in Supplementary Data.
HIF-2 α target gene identification
Chromatin Immunoprecipitations (ChIPs) were performed on 786.O cells as previously 
described (23) using rabbit polyclonal anti-sera to HIF-2α (PM9). Preimmune serum or IgG 
were used as negative controls. High-throughput sequencing was performed on libraries 
prepared from immunoprecipitated chromatin using the Illumina ChIP-Seq kit; 36-bp single 
end sequence analysis was performed on the Illumina GAII platform. The microarray 
analysis of 786.O cells in the presence of either control or HIF-2α siRNA was performed as 
previously described (24). Correlation of ChIP-seq data with microarray analysis of gene 
expression was performed using GSEA software Version 2 (www.broadinstitute.org/gsea/).
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Gene expression was quantified using TaqMan quantitative RT-PCR (Life Technologies) on 
the 786.O clones expressing the different VHL mutants used in the microarray study and on 
two additional independent clones. Probes references are available upon request.
Expression profiles of the 30 identified genes in clear cell renal cell carcinoma
The GSM14994 dataset (25), was used to analyse the expression of the 30 genes identified 
as direct target of the pVHL/HIF-2α pathway. The Affymetrix HT Human Genome U133A 
Arrays [[HT_HG-U133A] was normalized with the justRMA procedure in BrB Array Tools 
v.4.4.0. The signature corresponding to the comparaison of 52 clear cell renal cell carcinoma 
(VHL mutated) versus 11 normal kidney tissues was performed with the Class Comparison 
procedure on a restrictive list of 26 genes (probes for KCNIP3, TMEM141, ARRDC3, 
ERRFI1 were absent of the dataset (25)). All the details are given in Supplementary Data.
Results
The tumor occurrence in the family bearing the R200W mutation is associated with an 
additional event
The proband (III-2 – Fig. 1A) was originally identified as a heterozygous carrier of a single 
c.598C>T, p.Arg200Trp (R200W) mutation in the VHL gene (19, 20). He had a history of 
ccRCC and of CNS and retinal hemangioblastomas, and died age 62 of CNS complications. 
His father (II-1) died age 42 from a cerebellar hemangioblastoma, while his paternal 
grandparents died at an advanced age and had no known history of VHL manifestations. 
Two of his daughters, aged 28 and 36 (IV-2, IV-3), have a personal history of CNS and 
retinal hemangioblastomas. Patient IV-2 recently developed a ccRCC and a 
pheochromocytoma, and patient IV-3 a pancreatic neuroendocrine tumor. There is no 
erythrocytosis in the family, the hematocrit, red blood cells count and Epo levels being 
normal (Table S3). Due to the presence of pheochromocytoma and renal cell carcinoma, the 
family was classified as VHL Type-2B.
We performed in parallel haplotyping and genotyping of this family. To determine if the 
VHL disease occurred in the genetic context of the particular Chuvash core haplotype (18), 
we analyzed the single nucleotide polymorphisms (SNP) of the VHL region (Table 1). 
Despite the absence of known Chuvash ancestry, the mutated allele did localize to the 
Chuvash core haplotype (18).
The VHL-R200W mutation was confirmed by genotyping. Remarkably, we found a second 
heterozygous germline mutation, c.482G>A, p.Arg161Gln (R161Q) (Fig. 1B). Allele 
segregation showed that both mutations were present on the same allele; the mother and the 
healthy daughter (III-3 and IV-1) carried two wild type alleles, whereas the two affected 
daughters (IV-2 and 3) carried one copy each of the allele containing the two mutations (Fig. 
1A).
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Molecular dynamics simulations of pVHL mutants demonstrate a gradient in the loss of 
function with an additive effect of the double mutant
The impact of the single mutations (R200W and R161Q), and the double mutation (R200W
+R161Q), on the structure and dynamic behavior of pVHL was studied by molecular 
dynamics (MD) simulations. pVHL, a 213 amino acids protein, contains two domains, α and 
β, connected by a highly flexible linker L8 (3). The α-domain consists of 3 α-helices, H1, 
H2 and H3, forming a “box” motif that binds to adapter proteins. The substrate binding β-
domain consists of a seven-stranded β-sandwich and an α-helix H4 (Supplementary Fig. 
S2A) (21). Amino acids R200 and R161 are located in the helices H1 (α-domain) and H4 
(β–domain) respectively. Analysis of non-covalent contacts indicates that each mutation, 
R200 and R161, taken separately decreases the stabilizing inter-domains interactions, while 
these interactions are increased in the double mutant R200W+R161Q (Fig. 2; 
Supplementary Fig. S2B and S2C and Table S4). The inter-domain mobility of pVHL, 
evidenced by the rotation angle between the α– and β–domains, was previously shown to be 
of crucial importance for the correct positioning of the HIF substrate (26). Present MD 
simulations show that the values of this angle are almost similar for the wild-type protein 
(57°) and the R200W mutant (63°) (Fig. 2 and Supplementary Table S5). In contrast, the 
angle values for the mutants R161Q (77°) and R200W+R161Q (49°) differ strongly and 
represent two extreme conformations, open and closed, respectively.
Functional studies of the pVHL mutants show a gradual loss of function correlated to the 
phenotype severity
To evaluate the impact of these different mutations on HIF regulation, we performed a 
functional in vitro analysis by measuring the ability of the mutants to bind to a proline-
hydroxylated HIF-1α peptide (HIF-OH). The R200W mutation had no effect on the ability 
of pVHL to bind to HIF-OH compared to the wild type protein (Fig. 3A). In contrast, 
R161Q moderately affected this binding and R200W+R161Q completely prevented it. 
Therefore, the addition of the two mutations appeared to have an additional impact on the 
pVHL loss of function. We then performed a comprehensive in cellulo study. Each VHL 
mutant construct harboring missense mutation was then reintroduced into the VHL-defective 
renal cancer cell line 786.O, which over-expresses HIF-2α. Many attempts were 
unsuccessful to reintroduce classical VHL constructions in the cells, stably or transiently, 
toxicity (22) and non reproducible results being observed, especially for the wild type and 
the VHL-R200W vectors. We therefore used a lentiviral inducible system. The pVHL 
proteins were not tagged in order to provide protein products that fully mimicked the 
endogenous protein. Clones were selected based on equivalent mRNA level expression 
(Supplementary Fig. S3). Immunoblotting of clones expressing the wild-type or various 
mutated pVHL showed that the HIF-2α protein was differentially stabilized by the different 
mutants in the same order of severity (Fig. 3B) as was observed with the molecular 
dynamics simulations: wild type ≥ R200W > R161Q > R200W+R161Q. The inducible 
system showed weak variable leaks (Fig 3B, overexposed pVHL blot), we therefore 
compared mutants only after full induction for the following experiments. To pursue this 
further, transcriptomic profiles from cells expressing the main representative mutants of each 
type of VHL disease (C162F [Type-1], R167Q [Type-2B], Y98H [Type-2A], L188V 
[Type-2C]) were obtained by microarray analysis. A hierarchical unsupervised clustering 
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analysis showed a close correlation between the importance of the pVHL loss of function 
and the severity of the developed phenotype (Fig. 3C).
Gradual pVHL loss of function induces a gradual dysregulation of direct HIF-2α target 
genes
In order to determine the genes that may be responsible for tumor development in patients 
with VHL disease and the absence of tumors associated with the VHL-R200W mutation, we 
tried to identify relevant differentially regulated genes, but could not find any. 
Transcriptomics data are always difficult to analyze because the deregulation of one gene 
can induce a cascade of signalisation and induction of many indirect genes that drowns 
crucial informations on initiating events. Therefore, in order to focus on the first step of 
regulation by pVHL, and because HIF-2α, the main VHL target, is the most tumorigenic 
factor associated with cancer development (27), we focused on genes directly regulated by 
HIF-2α. We then correlated the list of genes regulated by the re-introduction of the wild-
type VHL into 786.O cells (283 genes were obtained from the above micro-array data) with 
a list of direct target genes of HIF-2α in 786.O cells (defined as the genes most regulated by 
HIF-2α siRNA within 250 kb of each HIF-2α binding site identified by ChIP-seq 
(Chromatin Immuno-precipitation and sequencing)) (Fig. 4A) (28). This yielded a set of 30 
genes that were stringently defined as being directly regulated by the pVHL/HIF-2α axis. 
We tested the expression level of 10 genes randomly selected from this set in different 786.0 
clones in which VHL mutants had been reintroduced (R200W and R161Q mutations, 
individually or in association, in which three independent clones with equivalent expression 
of VHL were obtained) (Fig. 4B). Overall, we observed a highly significant expression 
gradient for these genes (overall p-value< 1e-10) that matched precisely the order 
established above, with a function of the VHL-R200W mutation always very close to the 
wild type protein. Nine individual genes displayed a gradient response with a p-value<0.02 
(Supplementary Table S6).
The target genes of the pVHL/HIF-2α pathway are deregulated in renal cell carcinoma
In order to validate our identified genes on naturally occurring tumors, our set of 30 
candidate genes was analyzed via the webtool SEEK (Search-Based Exploration of 
Expression Compendium, http://seek.princeton.edu/) that prioritizes public human mRNA 
microarray datasets from many tumor types according to the genes of interest. When we 
analyzed our 30 genes with SEEK, they turned out to be significantly deregulated in 
microarrays from many series of renal cell carcinoma (data not shown). We selected one 
dataset of ccRCC with detailed VHL status (GSM14994 dataset (25)). The expression 
profiles of our 30 candidate genes were studied in VHL mutated ccRCC compared to normal 
kidney tissues. Among 26 genes with validated probes, 17 were differentially expressed with 
a threshold of 0.001 as nominal p-value (15 with a p-value around 1e-7 and less). They are 
shown on the heatmap (Fig. 5, Supplementary Table S7).
Discussion
We carried out a comprehensive study of the only family in which the VHL-R200W 
mutation was wrongly assumed to cause VHL disease (19, 20). We show that the R200W 
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mutation alone is definitely not associated with the disease because the family actually 
carries another pathogenic mutation, R161Q, on the same VHL allele, and the double 
mutated allele segregates with disease. Our SNP analysis showed that the doubled mutations 
lies on the Chuvash core haplotype transmitted with the R200W mutation. We can thus 
conclude that this haplotype does not contain any protective elements against cancer 
development and that the VHL mutations are, by themselves, predominantly responsible for 
manifestations of the VHL disease.
The family under study is VHL Type-2B (pheochromocytoma and high risk of kidney 
cancer), and the disease is caused by the combination of two germline mutations which, 
when considered separately, are associated with different phenotypes: R200W (either no 
symptoms or erythrocytosis) and R161Q (VHL Type-2A, pheochromocytomas and low risk 
of kidney cancer). Although it is not excluded that this family carry other genetic alterations 
(linked or not to VHL), we conducted a comprehensive functional and comparative analysis 
of these VHL mutations in order to clarify the complexity of genotype/phenotype 
correlations, and to understand the basis of either tumor development in patients with VHL 
disease or absence of cancer in carriers of the VHL-R200W mutation.
The molecular dynamics simulations of the pVHL mutants revealed a highly constrained and 
reduced inter-domain mobility of the double mutant compared to the single one. We suppose 
that the anti-cooperative allosteric effects of the two mutations impede optimal positioning 
of the substrate HIF. The results show a gradient in the loss of function of the different 
mutants with an additive effect of the double mutant: R200W+R161Q > R161Q > R200W 
≥wt.
In cellulo study was performed to compare these mutations to classical mutants involved in 
the different VHL phenotypes. As it is very difficult to reintroduce a tumor suppressor gene 
in a cell line, that have went through multiple selective pressure to delete it, without 
affecting its genetic status, we constructed a very sensitive cell line model with inducible 
untagged pVHL constructs. We chose the most studied ccRCC cell line (786.O, often used 
in therapeutic drug development). We did not identify any relevant candidate genes 
differentially regulated by the different mutants that may explain the occurrence of tumors or 
not. Although VHL plays roles in HIF-independent pathway, we then focused our functional 
studies on the HIF-2α pathway, HIF-2α being the isoform that plays a key role in the 
regulation of the expression of erythropoietin in erythrocytosis (13) and in the development 
of ccRCC (27) and pheochromocytoma (29, 30). We identified a set of genes directly 
regulated by the pVHL/HIF-2α pathway, and observed a distinct and graded ability of the 
different VHL mutants to regulate these genes: the more important the pVHL loss of 
function is, the more dysregulated the HIF-2α target genes are. To validate our results in 
naturally occurring tumors, we studied the expression profiles of the 30 genes identified 
above in massive human expression compendium that contains thousands of public 
expression datasets from various cancer types (SEEK). A large amount of kidney cancers 
datasets was significantly selected. The datasets from Beroukhim and collaborators (25) with 
known VHL status, were carefully analyzed, and 17 genes were highly overexpressed in 
ccRCC that have lost VHL. These genes have a role in oncogenesis (Supplementary Table 
S7), and some of them are overexpressed in tumors and associated with poor prognosis 
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(STC2, ADM in RCC (31–33); PFKFB3, NDRG1 in other tumors (see references in 
Supplementary Table S7). Being direct target genes of the VHL/HIF-2α pathway, these 
genes may in fact be driver oncogenes and may be involved in early oncogenic events. They 
should be explored as potential markers or targets for future drugs.
Altogether, our results show a gradual loss of function of the different VHL mutants that 
could explain the different associated phenotypes: (i) no tumor for R200W mutant with a 
function similar close to wild-type pVHL, (ii) an intermediate dysfunction leading to low 
risk of developing ccRCC for the R161Q mutant, (iii) and VHL Type-2B disease with high 
risk of ccRCC, as described in the present family where R200W+R161Q is associated with a 
severe loss of function. Remarkably, these findings do not fit the classical Knudson’s two-hit 
model of tumor suppressor gene (TSG), that implies that malignant transformation is the 
result of full inactivation of the TSG. Instead, and in addition to previously-published VHL 
functional studies (6, 10, 34, 35), they support the new «TSGs continuum model», 
demonstrated in mice, in which more flexible mechanisms including tissue specificity and 
gene dosage-sensitivity underlie tumor predisposition (1, 36). Our description of combined 
mutations in VHL, each proportionally impacting the patients phenotype, validates this 
model for the first time in humans and indicates that precisely-defined quantitative aspects 
of structural and functional dysregulation are key to tumor predisposition. Therefore, on the 
basis of our results and other studies, we can depict a model demonstrating a gradual tumor 
susceptibility correlated with a gradual pVHL loss of function (Fig. 6). (i) heterozygous 
carriers of germline VHL mutations with a weak effect (like R200W) never develop tumors 
(except for two isolated cases of CNS hemangioblastomas) (37). The function of the VHL-
R200W mutant is close but not totally equal to the wild type protein (Fig. 3C), and further 
studies targeting the genes dysregulated in this context are needed to understand the 
phenotype observed in homozygotes. In these patients, the exact mechanisms of the 
occurrence of erythrocytosis (achievement of a threshold that induces HIF and EPO 
production and/ or direct effect on erythroid progenitors proliferation due to particular 
properties of the VHL mutations) and occurrence of thrombotic events or PAH still need to 
be determined (9, 13, 14, 16, 38). Nevertheless, this mutation never induces sufficient 
selective pressure to allow tumorigenesis and as we evidenced, it may be due to an 
insufficient dysregulation of the tumorigenic HIF pathway. (ii) a moderate impact on pVHL 
function, whilst not enough to initiate renal cancer, appears sufficient for initiation of 
pheochromocytoma development from neural cells (notion of tissues specificity and quasi-
haploinsufficiency). No difference has been observed in pheochromocytoma occurrence 
between Type-2A and 2B (64% and 63% respectively) (5). However, it is noteworthy that 
germline VHL deletions are rarely associated with pheochromocytomas and a second hit 
(loss of the VHL wild-type allele) is often absent in the tumor (39). This observation 
suggests an obligate haploinsufficiency (when anti-tumorigenic mechanisms are induced by 
a complete loss of TSG usually due to the activation of fail-safe mechanisms (1)). Indeed, in 
neural cells, overexpression of EGLN3 (a target gene of HIF) induces apoptosis and is 
therefore incompatible with the development of pheochromocytoma (40). We can therefore 
conclude that, in pheochromocytoma, pVHL mutations function as hypomorphs, not as 
dominant negative alleles. (iii) a severe VHL loss of function is needed for ccRCC 
development. A gradient of predisposition depending on the VHL mutation has already been 
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suggested in ccRCC (6). The threshold of pVHL loss of activity could be reached with VHL 
Type-2A mutants (the typical Y98H mutation predispose to ccRCC in 3% of cases) (41) and 
a maximal risk of ccRCC development occurs with Type-2B mutants (severe pVHL loss of 
function) and Type-1 mutations (total VHL loss of function) (42).
It is remarkable that VHL mutations in erythrocytosis patients are different to those 
identified in patients with VHL (Supplementary Table S2) (5, 12). There are a few 
exceptions (43–47): for example, Y175C and L188V have been associated with both 
erythrocytosis and pheochromocytoma. These mutations may be considered as “borderline”, 
with a loss of function insufficient to induce renal cancer but still capable to cause 
pheochromocytoma. The L188V mutant illustrates perfectly this threshold: it is a typical 
VHL Type-2C mutation (48), its loss of function is difficult to assess (7, 34) and it has been 
described in rare patients with no symptoms or with erythrocytosis (43, 45–47).
Finally, our results suggest that the dysregulation of HIF may play a key role in the 
continuum model of tumor suppression by VHL. This model may be of major importance in 
our understanding of tumor risk in patients carrying mutations in other genes belonging the 
HIF pathway. Indeed, patients with germline mutations in PHD2/EGLN1 and HIF2A/EPAS1 
can develop pheochromocytomas or paragangliomas (equivalent to extra-adrenal 
pheochromocytomas) (49–51). A comparative study of PHD2 mutations showed a 
differential regulation of HIF that perfectly fits with the model described here (52). The 
absence of renal cancer in patients with PHD2 and HIF2A mutations could be explained by 
an only partial inactivation of PHD2 (possibly compensated by PHD1 and 3) (53), and by 
the persistence of some HIF-2α degradation (the germline activating mutations described in 
HIF2A gene being always outside of the major hydroxylated prolines).
In conclusion, the unique concurrence of two mutations that interact positively to perturb a 
specific structural feature of pVHL has allowed functional – clinical correlates, improving as 
a result our understanding of the genotype-phenotype associations in VHL disease. The 
additive effect of two pathogenic germline mutations supports the quantitative continuum 
model of tumor suppression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Genetic study of the family with a VHL disease carring the VHL-R200W mutation
(A) Pedigree and VHL sequencing. Solid symbols represent affected family members and 
symbols with a slash, deceased family members. Top left: central nervous system 
hemangioblastoma (CNS Hb) and retinal hemangioblastoma (Rt Hb); top right: pancreatic 
neuroendrocrine tumor (NET); bottom right: clear cell renal cell carcinoma (ccRCC); 
bottom left: pheochromocytoma (Pheo). The proband is indicated by an arrow and the 
patients sampled for genetic testing are indicated by symbol.  A plus sign represents 
family members harboring the R200W+R161Q/wt genotype and a minus sign, family 
members with a negative result on genetic testing for these mutations. Square brackets 
indicate a reconstituted genotype of a deceased patient by study of allele segregation.
(B): Representative sequence chromatograms of VHL in the area of the mutated 
nucleotide. Wild-type sequence of the germline DNA from the healthy parent (III-3) (top) is 
compared to the mutated allele of the daughter (IV-3) (bottom).
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Figure 2. Molecular dynamic study of the pVHL mutants
The structures of wild-type (wt) pVHL, R200W and R161Q single mutants and the R200W
+R161Q double mutant have been deduced by molecular dynamics (MD) simulations. The 
protein conformations, displayed in cartoons, illustrate the evolution of the rotation angle 
between α- and β-domain during the MD simulations. The MD snapshots corresponding to 
the initial conformation taken at 0 ns (in cyan) and the conformation displaying the 
maximum rotation angle (in red) are superimposed. The rotation angle is pictured by a cyan 
arrow and its maximum value is given in degrees.
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Figure 3. In vitro and in cellulo studies of the pVHL mutants
(A) In vitro analysis of HIF/pVHL binding. To evaluate the impact of the different 
mutations on HIF regulation, we performed a functional in vitro analysis by measuring the 
ability of the mutants to bind to a proline hydroxylated HIF-1α peptide. After in vitro 
transcription-translation, hemagglutinin (HA)-pVHL mutants were incubated with a 
hydroxylated-biotinylated peptide, corresponding to the HIF-1α Oxygen Dependent Domain 
(HIF-OH). After immunoprecipitation of the pVHL/HIF complexes with avidin beads and 
Nu-Page migration, we evaluated the amount of HA-pVHL bound by immunoblotting using 
an HA specific antibody.
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(B) HIF-2α and pVHL protein expression in 786.O cells transduced by different VHL 
inducible lentiviral constructs. We analyzed samples before (−) or after (+) induction with 
doxycyclin (DOX). The immunoblot of pVHL shows some leakage of the inducible system 
without DOX treatment. Actin protein expression was used as a loading control.
(C) Transcriptomic study of 786.O cells transduced with the different VHL mutants. 
The heatmap represents the relative expression (log ratio) of genes in 786.O cells transduced 
with wild type (wt) or mutant vectors compared with empty vector; one clone of each. 
Unsupervised hierarchical clustering was performed using an average linkage with cosine 
correlation as similarity metrics for both samples and genes, showing 200 sequences 
deregulated in at least two clones. These deregulated genes were selected using the 
following criteria: absolute fold change >2 and p-value calculated by the software Resolver 
< 1.10−5 for at least one experiment. The classification shows a correlation between the loss 
of function of the VHL mutations and the severity of the developed phenotype.
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(A): Identification of direct target genes regulated by pVHL/HIF-2α. The venn diagram 
illustrates the intersection between genes regulated by VHL (left) and direct HIF-2α target 
genes (right). Genes regulated by VHL were identified by microarray analysis of 786.O cells 
transduced with wild-type VHL (278 genes from 318 signatures). HIF-2α binding loci were 
identified by Chromatin-Immunoprecipitation followed by highthroughput sequencing 
(Chip-seq) (28) using both HIF-2α and HIF-1β antibodies. HIF-2α direct targets were then 
defined as the most regulated transcript (in a microarray analysis of 786.O cells treated with 
either control siRNA or HIF-2α siRNA) that lies within 250 kb of each of the HIF-2α 
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binding sites. The List of the 30 genes in the intersection of the Venn diagram is detailed 
below.
(B) TaqMan real-time quantitative RT-PCR analysis. Transcript quantification was 
performed on three independent clones of 786.O cells transduced with wild type (wt), 
mutant VHL or empty vectors. Relative expression was normalized to endogenous 18S 
rRNA and expressed as fold change compared with 786.O cells transduced with empty 
vector. Statistical calculations are detailed in Supplementary Table S6.
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Figure 5. Genes of the direct pVHL/HIF-2α pathway are overexpressed in naturally occurring 
ccRCC
Heatmap represents the 17 most dysregulated genes in VHL mutated ccRCC (on the right), 
versus normal kidney tissues (on the left). A contrast scale represents the under- (blue) and 
overexpression (orange) of the genes.
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Figure 6. A graded model for tumor suppression by VHL
Phenotypes of patients with VHL heterozygous germline mutations are represented on the 
top. A representative mutation of each type of phenotype is indicated and the corresponding 
loss of function of the mutants is represented by a black triangle. Tumor occurrence is 
indicated below. The different VHL mutations predispose to clear cell renal cell carcinomas 
(ccRCC) and pheochromocytomas (pheo), depending on their loss of function, with an 
ascending correlation. The VHL-R200W mutation is located at the bottom of the gradient 
that explains the absence of tumor occurrence.
Couvé et al. Page 22




































































































































































































































































































































































































































































Cancer Res. Author manuscript; available in PMC 2017 August 14.
